Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.

The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group. From a turnover of Rs. 250 crores in 1995, the group posted revenues of Rs. 6300 crores in FY13.

Today, Zydus Cadila holds a commanding position in the domestic pharma industry sweepstakes. Globally, the group has a strong presence in the regulated markets of the US, Europe (France & Spain), Japan and the high profile markets of Latin America and South Africa. It also has a strong presence in 25 other emerging markets worldwide. It aims to be a leading global healthcare provider with a robust product pipeline; opening up new pathways through innovation and quality excellence, achieve sales of Rs.10000 crore by 2015 and be a research-based company by 2020.

Supporting its marketing prowess is the group’s manufacturing facilities. The group has state-of-the-art vertically integrated manufacturing facilities for APIs and formulations, spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. Of these, five facilities are USFDA approved.

The group has a team of around 1000 research professionals spearheading its research and development programme of which nearly 400 scientists alone are involved in the NME research programme at the Zydus Research Centre, the group’s state-of-the-art R&D centre.

Zydus Cadila is supported by a team of over 16,000 people worldwide, comprising professionals, research scientists, medical advisors and workers.

Regarding the distribution of Exemptia in India Zydus Cadila said it will offer a dedicated support programme for patients and caregivers which will provide support and information regarding access, adherence and awareness.

Zydus Cadila will create a new division – Zydus Biovation – to market the drug. This new business will support the drug’s launch with a series of medical education events and scientific symposia for healthcare professionals in India.

Deputy managing director of Zydus Cadila, Dr Sharvil Patel said: “This therapy will offer a new lease of life to millions in India who did not have access to this therapy so far. We are happy to offer them hope, freedom from pain and better quality of life through Exemptia.”

In December 2014, Cadila Healthcare Ltd., launched in India the first Adalimumab biosimilar, under the name Exemptia.

For more information visit www.zyduscadila.com